Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma

Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma

BackgroundAntiangiogenic agents that specifically target vascular endothelial growth factor receptor (VEGFR), such as sunitinib, have been utilized as the standard therapy for metastatic clear cell renal cell carcinoma (ccRCC) patients. However, most patients eventually show no responses to the targ...

Full description

Bibliographic Details
Main Authors:	Yuang Wei, Xinglin Chen, Xiaohan Ren, Bao Wang, Qian Zhang, Hengtao Bu, Jian Qian, Pengfei Shao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-07-01
Series:	Frontiers in Genetics
Subjects:	sunitinib resistance drug resistance antiangiogenic therapy TKIs clear cell renal cell carcinoma human myxovirus resistance protein 2
Online Access:	https://www.frontiersin.org/articles/10.3389/fgene.2021.680369/full

Similar Items

PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance
by: Chenchen Feng, et al.
Published: (2021-09-01)

LPPR5 Expression in Glioma Affects Growth, Vascular Architecture, and Sunitinib Resistance
by: Lena Stange, et al.
Published: (2022-03-01)

Sunitinib resistance in renal cell carcinoma
by: Christudas Morais
Published: (2014-04-01)

Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells
by: Magdalena Rausch, et al.
Published: (2021-06-01)

Metabolomic Analysis to Elucidate Mechanisms of Sunitinib Resistance in Renal Cell Carcinoma
by: Tomonori Sato, et al.
Published: (2020-12-01)

A Fatty Acid Metabolism Signature Associated With Clinical Therapy in Clear Cell Renal Cell Carcinoma
by: Zhihao Wei, et al.
Published: (2022-07-01)

The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer
by: Kaamar Azijli, et al.
Published: (2016-01-01)

Mx bio adjuvant for enhancing immune responses against influenza virus
by: Sina Soleimani, et al.
Published: (2015-06-01)

The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance
by: Harrison Sicheng Lin, et al.
Published: (2022-01-01)

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
by: Asim Amin, et al.
Published: (2018-10-01)

Long Non-coding RNA CCAT1 Acts as an Oncogene and Promotes Sunitinib Resistance in Renal Cell Carcinoma
by: Liping Shan, et al.
Published: (2020-09-01)

Corrigendum: Long non-coding RNA CCAT1 acts as an oncogene and promotes sunitinib resistance in renal cell carcinoma
by: Liping Shan, et al.
Published: (2023-08-01)

Insulin Resistance and Pellino-1 Mediated Decrease in the Activities of Vasodilator Signaling Contributes to Sunitinib-Induced Hypertension
by: Yang Liu, et al.
Published: (2021-03-01)

Effect of enhanced expression of connexin 43 on sunitinib-induced cytotoxicity in mesothelioma cells
by: Miaki Uzu, et al.
Published: (2015-05-01)

Clear Cell Renal Cell Carcinoma, Diagnostic and Therapeutic Difficulties, Case Report and Literature Review
by: Weronika Stolpa, et al.
Published: (2022-09-01)

Transgelin Contributes to a Poor Response of Metastatic Renal Cell Carcinoma to Sunitinib Treatment
by: Pavla Bouchalova, et al.
Published: (2021-09-01)

Integrated mRNA and miRNA Transcriptomic Analyses Reveals Divergent Mechanisms of Sunitinib Resistance in Clear Cell Renal Cell Carcinoma (ccRCC)
by: María Armesto, et al.
Published: (2021-08-01)

Sunitinib treatment does not improve blood supply but induces hypoxia in human melanoma xenografts
by: Gaustad Jon-Vidar, et al.
Published: (2012-09-01)

Photochemically-Induced Release of Lysosomal Sequestered Sunitinib: Obstacles for Therapeutic Efficacy
by: Judith Jing Wen Wong, et al.
Published: (2020-02-01)

Dysregulation of the Sirt5/IDH2 axis contributes to sunitinib resistance in human renal cancer cells
by: Liang Meng, et al.
Published: (2021-03-01)

Establishment of Sunitinib-Resistant Xenograft Model of Renal Cell Carcinoma and the Identification of Drug-Resistant Hub Genes and Pathways
by: Xie Y, et al.
Published: (2021-12-01)

Shikonin Inhibits Cell Growth of Sunitinib-Resistant Renal Cell Carcinoma by Activating the Necrosome Complex and Inhibiting the AKT/mTOR Signaling Pathway
by: Sascha D. Markowitsch, et al.
Published: (2022-02-01)

Interaction between Wnt/β-catenin signaling pathway and EMT pathway mediates the mechanism of sunitinib resistance in renal cell carcinoma
by: Fangzhen Cai, et al.
Published: (2024-02-01)

Evidence for a Novel Antiviral Mechanism of Teleost Fish: Serum-Derived Exosomes Inhibit Virus Replication through Incorporating Mx1 Protein
by: Jian He, et al.
Published: (2021-09-01)

Knockdown of KLF5 ameliorates renal fibrosis in MRL/lpr mice via inhibition of MX1 transcription
by: Shanshan Tao, et al.
Published: (2023-07-01)

Sunitinib induced resistance of endothelial cells by up-regulating P-glycoprotein and PI3K/Akt pathway
by: Rong Zhang, et al.
Published: (2022-09-01)

Targeting VEGF-VEGFR Pathway by Sunitinib in Peripheral Primitive Neuroectodermal Tumor, Paraganglioma and Epithelioid Hemangioendothelioma: Three Case Reports
by: Tiziana Prochilo, et al.
Published: (2013-02-01)

The evaluation of the Myxovirus Resistance 1 protein in serum and saliva to monitor disease activation in primary Sjögren’s syndrome
by: Yasemin Gul Aydemir, et al.

From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib
by: Amal Kamal Abdel-Aziz, et al.
Published: (2017-10-01)

Recurrent multiple liver metastases of clear cell renal cell carcinoma with a significant response to sunitinib after nivolumab treatment
by: Kouki Tada, et al.
Published: (2023-01-01)

Ιmpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer
by: Theofanis Vasileiadis, et al.
Published: (2019-04-01)

Corrigendum: From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib
by: Amal Kamal Abdel-Aziz, et al.
Published: (2018-02-01)

The association between blood MxA mRNA and long-term disease activity in early multiple sclerosis
by: Eline M. E. Coerver, et al.
Published: (2022-08-01)

Acute Acalculous Cholecystitis Associated with Sunitinib Treatment for Renal Cell Carcinoma
by: Se Woong Choi, et al.
Published: (2020-02-01)

Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinoma
by: Daniel Y.C. Heng, et al.
Published: (2011-12-01)

Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinoma
by: Daniel Y.C. Heng, et al.
Published: (2011-12-01)

Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first‐line treatment for advanced EGFR‐mutant non‐small cell lung cancer
by: Zhonghan Zhang, et al.
Published: (2020-06-01)

Integrated genomic and proteomic analyses identify PYGL as a novel experimental therapeutic target for clear cell renal cell carcinoma
by: Mingyong Li, et al.
Published: (2024-03-01)

Final Report of the First Refractory Germ Cell Tumor Treated with Sunitinib Malate
by: Joan Manel Gasent Blesa, et al.
Published: (2009-12-01)

Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma
by: Ninadh M. D’Costa, et al.
Published: (2020-02-01)